Treats hyperthyroidism, Graves disease, and thyroid cancer.
|
Prototype Med
|
Radioactive Iodine
|
|
Iodine 131
|
|
Hyperthyroidism (Graves’ disease)
|
|
Thyroid cancer
|
|
Hypothyroidism (expected for most clients, but still requires drug thera- py)
|
|
Bone marrow depression (rare)
|
|
Radiation sickness (rare)
|
|
Monitor thyroid function.
|
|
Monitor for indications of thyroid dysfunction (drowsiness, depression, weight gain, edema, bradycardia, anorexia, cold intolerance, dry skin, menorrhagia).
|
|
Monitor CBC and platelet count at baseline and periodically thereafter.
|
|
Monitor for indications of anemia, leukopenia, and thrombocytopenia.
|
|
Monitor for manifestations of radiation sickness (hematemesis, epistax- is, intense nausea, vomiting).
|
|
Give orally.
|
|
Obtain a negative pregnancy test before administration.
|
|
Measure baseline vital signs and weight and monitor periodically there- after.
|
|
Dosage is miniscule for thyroid disorders, larger for thyroid cancers
|
|
Initiate radiation precautions for large doses (limited contact, increased fluids, body waste disposal per facility protocol).
|
|
Watch for and report anxiety, drowsiness, depression, weight gain, swelling, slow heart rate, appetite loss, cold intolerance, dry skin.
|
|
Report fever, sore throat, weakness, or fatigue.
|
|
Report bloody vomit, nosebleeds, or severe nausea and vomiting.
|
|
Pregnancy: teratogenic effects
|
|
Lactation
|
|
Children prior to puberty
|
|
Other antithyroid drugs reduce uptake.
|
No comments yet.
Cheatography n. The art of mapping complex subjects into clear, instantly navigable reference guides.
